{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T03:41:56Z","timestamp":1784950916126,"version":"3.55.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011082","name":"School of Medicine, University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","award":["1000000163"],"award-info":[{"award-number":["1000000163"]}],"id":[{"id":"10.13039\/100011082","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK 2873"],"award-info":[{"award-number":["GRK 2873"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bcp.2025.117485","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T01:31:11Z","timestamp":1761787871000},"page":"117485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P1","title":["Discovery and characterization of quinoxaline and quinoline carboxamides as allosteric cannabinoid receptor modulators"],"prefix":"10.1016","volume":"243","author":[{"given":"Chunyang","family":"Bi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andhika B.","family":"Mahardhika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanigaimalai","family":"Pillaiyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0013-6624","authenticated-orcid":false,"given":"Christa E.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.117485_b0005","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0026-895X(25)09876-1","article-title":"Determination and characterization of a cannabinoid receptor in rat brain","volume":"34","author":"Devane","year":"1988","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117485_b0010","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s00103-019-02964-4","article-title":"Fortschritte in der Cannabis-Forschung aus pharmazeutisch-chemischer Sicht (Progress in cannabis research from a pharmaceutical chemist\u2019s point of view)","volume":"62","author":"M\u00fcller","year":"2019","journal-title":"Bundesgesundheitsbl. Gesundheitsforsch. Gesundheitsschutz"},{"key":"10.1016\/j.bcp.2025.117485_b0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: \u03949-tetrahydrocannabinol, cannabidiol and \u03949-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117485_b0020","doi-asserted-by":"crossref","first-page":"9605","DOI":"10.1038\/s41598-022-13724-x","article-title":"Cell type specific cannabinoid CB1 receptor distribution across the human and non-human primate cortex","volume":"12","author":"Chou","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2025.117485_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110301","article-title":"The synthetic CB1 cannabinoid receptor selective agonists: putative medical uses and their legalization","volume":"110","author":"Coronado-\u00c1lvarez","year":"2021","journal-title":"Prog Neuro-Psychoph"},{"key":"10.1016\/j.bcp.2025.117485_b0030","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1017\/S1462399409000957","article-title":"Emerging role of the CB2 cannabinoid receptor in immune regulation and therapeutic prospects","volume":"11","author":"Cabral","year":"2009","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.bcp.2025.117485_b0035","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s43440-021-00270-y","article-title":"Cannabinoid-based therapy as a future for joint degeneration. Focus on the role of CB2 receptor in the arthritis progression and pain: an updated review","volume":"73","author":"Bryk","year":"2021","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.bcp.2025.117485_b0040","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1021\/jm301527r","article-title":"Design, synthesis, and pharmacological properties of new heteroarylpyridine\/heteroarylpyrimidine derivatives as CB2 cannabinoid receptor partial agonists","volume":"56","author":"Tabrizi","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117485_b0045","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/346561a0","article-title":"Structure of a cannabinoid receptor and functional expression of the cloned cDNA","volume":"346","author":"Matsuda","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2025.117485_b0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2025.117485_b0055","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejmech.2018.09.070","article-title":"Synthesis of novel 2-(1-adamantanylcarboxamido)thiophene derivatives. Selective cannabinoid type 2 (CB2) receptor agonists as potential agents for the treatment of skin inflammatory disease","volume":"161","author":"Mugnaini","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117485_b0060","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1111\/j.1476-5381.2011.01731.x","article-title":"So what do we call GPR18 now?","volume":"165","author":"Alexander","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117485_b0065","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1111\/bph.12746","article-title":"Activation of GPR18 by cannabinoid compounds: a tale of biased agonism","volume":"171","author":"Console-Bram","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117485_b0070","doi-asserted-by":"crossref","unstructured":"G. Godlewski, G. Kunos, Overview of nonclassical cannabinoid receptors, in: M.E. Abood, R.G. Sorensen, N. Stella (Eds.), endoCANNABINOIDS: Actions at non-CB1\/CB2 cannabinoid receptors, Springer New York, New York, NY, 2013, pp. 3\u201327. https:\/\/doi.org\/10.1007\/978-1-4614-4669-9_1.","DOI":"10.1007\/978-1-4614-4669-9_1"},{"key":"10.1016\/j.bcp.2025.117485_b0075","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/j.1476-5381.2012.02019.x","article-title":"GPR18 in microglia: implications for the CNS and endocannabinoid system signalling","volume":"167","author":"McHugh","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117485_b0080","doi-asserted-by":"crossref","unstructured":"D. McHugh, H.B. Bradshaw, GPR18 and NAGly signaling: New members of the endocannabinoid family or distant cousins?, in: M.E. Abood, R.G. Sorensen, N. Stella (Eds.), endoCANNABINOIDS: Actions at Non-CB1\/CB2 Cannabinoid Receptors, Springer New York, New York, NY, 2013, pp. 135\u2013142. https:\/\/doi.org\/10.1007\/978-1-4614-4669-9_6.","DOI":"10.1007\/978-1-4614-4669-9_6"},{"key":"10.1016\/j.bcp.2025.117485_b0085","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1111\/j.1476-5381.2011.01497.x","article-title":"Delta(9)-Tetrahydrocannabinol and N-arachidonylglycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells","volume":"165","author":"McHugh","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117485_b0090","doi-asserted-by":"crossref","first-page":"12328","DOI":"10.1074\/jbc.M806516200","article-title":"Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay","volume":"284","author":"Yin","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2025.117485_b0095","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1039\/C3MD00394A","article-title":"Bicyclic imidazole-4-one derivatives: a new class of antagonists for the orphan G protein-coupled receptors GPR18 and GPR55","volume":"5","author":"Rempel","year":"2014","journal-title":"MedChemComm"},{"key":"10.1016\/j.bcp.2025.117485_b0100","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1021\/jm4005175","article-title":"Antagonists for the orphan G protein-coupled receptor GPR55 based on a coumarin scaffold","volume":"56","author":"Rempel","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117485_b0105","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1126\/science.1470919","article-title":"Isolation and structure of a brain constituent that binds to the cannabinoid receptor","volume":"258","author":"Devane","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.bcp.2025.117485_b0110","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0006-2952(95)00109-D","article-title":"Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors","volume":"50","author":"Mechoulam","year":"1995","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117485_b0115","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.3390\/ijms21145064","article-title":"Targeting cannabinoid receptors: current status and prospects of natural products","volume":"21","author":"An","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117485_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116035","article-title":"Synthesis and biological evaluation of a ring analogs of the selective CB2 inverse agonist SMM-189","volume":"33","author":"Alghamdi","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117485_b0125","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3390\/ph15030359","article-title":"Medical cannabis in pediatric oncology: friend or foe?","volume":"15","author":"Malach","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bcp.2025.117485_b0130","first-page":"785","article-title":"Magnolol and derivatives as lead structures for the development of GPR55 antagonists","volume":"10","author":"Fuchs","year":"2014","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.bcp.2025.117485_b0135","first-page":"28","article-title":"Integrative medicine: cannabis and cannabis-related drugs","volume":"505","author":"Moss","year":"2021","journal-title":"FP Essent."},{"key":"10.1016\/j.bcp.2025.117485_b0140","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0960-894X(95)00573-C","article-title":"Structure activity relationships of tetrahydrocannabinol analogues on human cannabinoid receptors","volume":"6","author":"Gareau","year":"1996","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2025.117485_b0145","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11419-018-0415-z","article-title":"Pharmacological evaluation of new constituents of \u201cSpice\u201d: synthetic cannabinoids based on indole, indazole, benzimidazole and carbazole scaffolds","volume":"36","author":"Schoeder","year":"2018","journal-title":"Forensic Toxicol."},{"key":"10.1016\/j.bcp.2025.117485_b0150","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/dta.3037","volume":"13","author":"Pike","year":"2021","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.bcp.2025.117485_b0155","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1021\/acsmedchemlett.7b00129","article-title":"Development of highly affine and selective fluorinated cannabinoid type 2 receptor ligands","volume":"8","author":"Moldovan","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2025.117485_b0160","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/dta.3035","volume":"13","author":"Grafinger","year":"2021","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.bcp.2025.117485_b0165","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.3390\/molecules18043972","article-title":"Design, synthesis, binding and docking-based 3D-QSAR studies of 2-pyridylbenzimidazoles-a new family of high affinity CB1 cannabinoid ligands","volume":"18","author":"Mella-Raip\u00e1n","year":"2013","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2025.117485_b0170","doi-asserted-by":"crossref","first-page":"5391","DOI":"10.1021\/jm3003334","article-title":"Design, synthesis, and pharmacological characterization of indol-3-ylacetamides, indol-3-yloxoacetamides, and indol-3-ylcarboxamides: potent and selective CB2 cannabinoid receptor inverse agonists","volume":"55","author":"Pasquini","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117485_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105649","article-title":"Pharmacotherapy of obesity: an update","volume":"169","author":"Cignarella","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2025.117485_b0180","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1021\/ml300235q","article-title":"Magnolia extract, magnolol, and metabolites: activation of cannabinoid CB2 receptors and blockade of the related GPR55","volume":"4","author":"Rempel","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2025.117485_b0185","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/0024-3205(95)00175-6","article-title":"AM630, a competitive cannabinoid receptor antagonist","volume":"56","author":"Pertwee","year":"1995","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2025.117485_b0190","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/sj.bjp.0702351","article-title":"Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630","volume":"126","author":"Ross","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117485_b0195","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1124\/mol.105.016162","article-title":"Allosteric modulation of the cannabinoid CB1 receptor","volume":"68","author":"Price","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117485_b0200","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.bjp.0707347","article-title":"Wong Kai In, PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats","volume":"152","author":"Horswill","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117485_b0205","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202200493","article-title":"Design, synthesis, and structure\u2013activity relationships of diindolylmethane derivatives as cannabinoid CB2 receptor agonists","volume":"356","author":"Mahardhika","year":"2023","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bcp.2025.117485_b0210","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.69","article-title":"Behavioral effects of the cannabinoid CB1 receptor allosteric modulator ORG27569 in rats","volume":"2","author":"Ding","year":"2014","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.bcp.2025.117485_b0215","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/FBP.0000000000000027","article-title":"In vivo pharmacological evaluation of the CB1-receptor allosteric modulator ORG27569","volume":"25","author":"Gamage","year":"2014","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117485_b0220","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1055\/s-0037-1609152","article-title":"Aminocarbonylation of N-containing heterocycles with aromatic amines using Mo(CO)6","volume":"50","author":"Mamone","year":"2018","journal-title":"Synthesis-Stuttgart"},{"key":"10.1016\/j.bcp.2025.117485_b0225","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5012\/jkcs.2013.57.2.241","article-title":"Design, synthesis and antibacterial activity studies of novel quinoline carboxamide derivatives","volume":"57","author":"Shivaraj","year":"2013","journal-title":"J. Korean Chem. Soc."},{"key":"10.1016\/j.bcp.2025.117485_b0230","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3390\/molecules17010613","article-title":"Investigating the spectrum of biological activity of substituted quinoline-2-carboxamides and their isosteres","volume":"17","author":"Gonec","year":"2012","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2025.117485_b0235","doi-asserted-by":"crossref","first-page":"9896","DOI":"10.1021\/acs.jmedchem.3c02423","article-title":"Potent, selective agonists for the cannabinoid-like orphan G protein-coupled receptor GPR18: a promising drug target forcancer and immunity","volume":"67","author":"Mahardhika","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117485_b0240","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1016\/j.bmc.2009.02.027","article-title":"Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists","volume":"17","author":"Behrenswerth","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117485_b0245","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1021\/acsptsci.2c00020","article-title":"Agonist-dependent coupling of the promiscuous adenosine A2B receptor to G\u03b1 protein subunits","volume":"5","author":"Voss","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.bcp.2025.117485_b0250","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0003-2697(90)90113-N","article-title":"A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid","volume":"189","author":"Nordstedt","year":"1990","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.bcp.2025.117485_b0255","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41589-019-0387-2","article-title":"Structure of an allosteric modulator bound to the CB1 cannabinoid receptor","volume":"15","author":"Shao","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2025.117485_b0260","unstructured":"Molecular Operating Environment (MOE) 2022.02, in: -.S.S.W. Chemical Computing Group ULC, Montreal, Canada (Ed.) Chemical Computing Group ULC, 910-1010 Sherbrooke St. W., Montreal, Canada."},{"key":"10.1016\/j.bcp.2025.117485_b0265","doi-asserted-by":"crossref","first-page":"e4792","DOI":"10.1002\/pro.4792","article-title":"UCSF ChimeraX: tools for structure building and analysis","volume":"32","author":"Meng","year":"2023","journal-title":"Protein Sci."},{"key":"10.1016\/j.bcp.2025.117485_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114138","article-title":"Development of high-affinity fluorinated ligands for cannabinoid subtype 2 receptor, and invitro evaluation of a radioactive tracer for imaging","volume":"232","author":"Modemann","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117485_b0275","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/jpet.116.232561","article-title":"Functional selectivity of CB2 cannabinoid receptor ligands at a canonical and noncanonical pathway","volume":"358","author":"Dhopeshwarkar","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2025.117485_b0280","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1038\/sj.ijo.0803272","article-title":"The pharmacology of cannabinoid receptors and their ligands: an overview","volume":"30","author":"Pertwee","year":"2006","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.bcp.2025.117485_b0285","doi-asserted-by":"crossref","first-page":"1.22.1","DOI":"10.1002\/0471141755.ph0122s11","article-title":"Quantification of allosteric interactions at G protein-coupled receptors using radioligand binding assays","volume":"11","author":"Christopoulos","year":"2000","journal-title":"Curr. Protoc. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117485_b0290","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/pr.54.2.323","article-title":"G protein-coupled receptor allosterism and complexing","volume":"54","author":"Christopoulos","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bcp.2025.117485_b0295","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.2042-7158.1997.tb06112.x","article-title":"Application of an allosteric ternary complex model to the technique of pharmacological resultant analysis","volume":"49","author":"Christopoulos","year":"2011","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117485_b0300","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.drugalcdep.2014.08.004","article-title":"Effects of the cannabinoid CB1 receptor allosteric modulator ORG 27569 on reinstatement of cocaine- and methamphetamine-seeking behavior in rats","volume":"143","author":"Jing","year":"2014","journal-title":"Drug Alcohol Depen."},{"key":"10.1016\/j.bcp.2025.117485_b0305","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1124\/mol.112.080879","article-title":"CB1 receptor allosteric modulators display both agonist and signaling pathway specificity","volume":"83","author":"Baillie","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117485_b0310","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/med.21418","article-title":"Allosteric modulation: an alternate approach targeting the cannabinoid CB1 receptor","volume":"37","author":"Nguyen","year":"2017","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bcp.2025.117485_b0315","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1124\/mol.115.099192","article-title":"Biased agonism and biased allosteric modulation at the CB1 cannabinoid receptor","volume":"88","author":"Khajehali","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117485_b0320","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/bph.12329","article-title":"Real-time characterization of cannabinoid receptor 1 (CB1) allosteric modulators reveals novel mechanism of action","volume":"170","author":"Cawston","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117485_b0325","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1021\/ml400176n","article-title":"Discovery of ML314, a brain penetrant nonpeptidic \u03b2-arrestin biased agonist of the neurotensin NTR1 receptor","volume":"4","author":"Peddibhotla","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2025.117485_b0330","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1021\/acschembio.6b00291","article-title":"ML314: a biased neurotensin receptor ligand for methamphetamine abuse","volume":"11","author":"Barak","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bcp.2025.117485_b0335","doi-asserted-by":"crossref","first-page":"8357","DOI":"10.1021\/acs.jmedchem.9b00340","article-title":"Discovery of \u03b2-arrestin biased, orally bioavailable, and cns penetrant neurotensin receptor 1 (NTR1) allosteric modulators","volume":"62","author":"Pinkerton","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117485_b0340","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.cell.2020.04.053","article-title":"\u03b2-Arrestin-biased allosteric modulator of NTSR1 selectively attenuates addictive behaviors","volume":"181","author":"Slosky","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2025.117485_b0345","doi-asserted-by":"crossref","unstructured":"M.N. Moore, K.L. Person, A. Alwin, C. Krusemark, N. Foster, C. Ray, A. Inoue, M.R. Jackson, M.J. Sheedlo, L.S. Barak, E.M. Fernandez de Velasco, S.H. Olson, L.M. Slosky, Design of allosteric modulators that change GPCR G protein subtype selectivity, bioRxiv (2024) 2024.11.20.624209, https:\/\/doi.org\/10.1101\/2024.11.20.624209.","DOI":"10.1101\/2024.11.20.624209"},{"key":"10.1016\/j.bcp.2025.117485_b0350","doi-asserted-by":"crossref","first-page":"15453","DOI":"10.1038\/srep15453","article-title":"Endogenous vs exogenous allosteric modulators in GPCRs: a dispute for shuttling CB1 among different membrane microenvironments","volume":"5","author":"Stornaiuolo","year":"2015","journal-title":"Sci. Rep."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225007506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225007506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T04:58:48Z","timestamp":1775797128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225007506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":70,"alternative-id":["S0006295225007506"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117485","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery and characterization of quinoxaline and quinoline carboxamides as allosteric cannabinoid receptor modulators","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117485","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117485"}}